CDKN2A and non-small cell lung carcinoma: We next looked at the expression of RB and the cyclin dependent kinase inhibitor p16INK4A (CDKN2A) by IHC in relation to RB1 mutation status in the NSCLC cohort (Figure 3 and Table 3).